Episurf Medical reaches milestone of 600 implants

Report this content

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 600th surgery with the Episealer® implant in the coming weeks. The company recently communicated that the patient groups who have had the implant for more than 2 and 3 years had grown, and today the company announces further growth in the overall patient population.   

“This is yet another important milestone, and I am very pleased with the good results that we can see, in addition to the growing volumes", says Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical.   

“This is great news for us. Knee surgery is an orthopaedic segment of significant size, and the old treatment patterns are established. The problem is that for a large group, efficient treatments are lacking, why we are meeting a demand for new alternatives. A demand coming from both patients and surgeons. Establishing a new technology as a new standard in this market segment comes with a great burden of proof. That’s all expected. But what we can say, it that what is being asked for from us, we are delivering. More and more surgeons are adopting this new technology, and we are in constant dialogue with a vast number of potential users. We are still at the beginning of our establishment, but we have come this far with minimal clinical evidence. I am very excited about the steps we will be able to take as more evidence is available and as we execute on our strategy”, says Pål Ryfors, CEO Episurf Medical.   

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.15 CEST on 18 September 2019.